# The Proactive Screening and diagnosis of mild cognitive impairment and depression in patients aged 65 and over: An Implementation Study

> **NIH NIH R44** · MIRO HEALTH INC · 2023 · $980,904

## Abstract

Project Summary
The proposed program aims to complete the work needed for Miro Health to finalize FDA
approval for the automated diagnosis of amnestic MCI (aMCI) which often leads to Alzheimer’s
and related dementias (ADRD), non-amnestic MCI (naMCI), and late life depression (LLD). The
work involves the optimization of our data processing pipeline and digital signal processing
methods and the refinement of our machine learning algorithms based on data types collected
via real-world settings rather than through clinical research environments. Our objective is to
improve patient outcomes and reduce healthcare costs by providing a universally available, self-
administered mobile brain assessment and diagnostic platform.
Prospective study participants will be recruited from clinics and the community. Participants will
participate in novel mobile assessments and traditional cognitive and psychiatric assessments.
The resulting data will be used to: (1) Assess usability of Miro for remote assessment; (2)
Improve quantification of functional abilities and add RDoC metadata labels to Platform; (3)
Refine A.I. models for the diagnosis of aMCI, naMCI, LLD, and comorbid MCI+LLD.
Because late-life depression often mimics MCI and co-occurring depression may hasten the
progression of MCI toward dementia, the identification and proper treatment of depression may
resolve some apparent cases of MCI and slow the progression of others. Comorbid presentation
of brain disorders is common and the increased availability of tools that can accurately and
reliably identify complex comorbidities will improve care for our neediest patients.
The work involved in this program will enhance Miro Health’s Mobile Research Platform. The
introduction of RDoC metadata labels into our Mobile Research Platform’s metadata schema
will help standardize clinical research, dramatically reduce the number of staff needed per
study, and support massive scalability. Enhancing tools that yield precise, uniform data sets will
improve the power, interpretability, and generalizability of studies examining disease etiology,
genetic risk factors, and interventions.

## Key facts

- **NIH application ID:** 10706563
- **Project number:** 5R44AG079760-02
- **Recipient organization:** MIRO HEALTH INC
- **Principal Investigator:** Shenly Glenn
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $980,904
- **Award type:** 5
- **Project period:** 2022-09-30 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706563

## Citation

> US National Institutes of Health, RePORTER application 10706563, The Proactive Screening and diagnosis of mild cognitive impairment and depression in patients aged 65 and over: An Implementation Study (5R44AG079760-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10706563. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*